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Trained immunity leads to long-term
protection, but strategies to boost it
require further investigation. Saz-Leal
et al. show that myeloid SHIP-1 deletion
enhances trained immunity, improving
the response to pathogen-specific or
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Pharmacological inhibition of SHIP-1 also
potentiates this phenomenon, thereby
revealing a potential tool to harness
trained immunity.
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b-Glucan-induced trained immunity in myeloid cells
leads to long-term protection against secondary
infections. Although previous studies have charac-
terized this phenomenon, strategies to boost trained
immunity remain undefined.We found that b-glucan-
trained macrophages from mice with a myeloid-
specific deletion of the phosphatase SHIP-1
(LysMDSHIP-1) showed enhanced proinflammatory
cytokine production in response to lipopolysaccha-
ride. Following b-glucan training, SHIP-1-deficient
macrophages exhibited increased phosphorylation
of Akt andmTOR targets, correlatingwith augmented
glycolytic metabolism. Enhanced training in the
absence of SHIP-1 relied on histone methylation
and acetylation. Trained LysMDSHIP-1 mice pro-
duced increased amounts of proinflammatory
cytokines upon rechallenge in vivo and were
better protected against Candida albicans infection
compared with control littermates. Pharmacological
inhibition of SHIP-1 enhanced trained immunity
against Candida infection in mouse macrophages
and human peripheral blood mononuclear cells. Our
data establish proof of concept for improvement
of trained immunity and a strategy to achieve it by
targeting SHIP-1.
INTRODUCTION
Innate immune cells challenged with certain stimuli undergo
long-lasting changes that result in improved response to a sec-
ond challenge by the same or different microbial insult, a process
referred to as trained immunity (Quintin et al., 2012). Stimuli
driving trained immunity lead to a shift to aerobic glycolysis
(Arts et al., 2016b), accompanied by sustained changes in the
epigenome, mainly via histone methylation and acetylation (Ne-
tea et al., 2016). Among trained immunity inducers, exposure to a
low dose of Candida albicans or the fungal cell wall component1118 Cell Reports 25, 1118–1126, October 30, 2018 ª 2018 The Auth
This is an open access article under the CC BY-NC-ND license (http://b-glucan protects mice from secondary lethal systemic candidi-
asis (Bistoni et al., 1986) or heterologous Staphylococcus aureus
septicemia (Di Luzio and Williams, 1978). This acquired resis-
tance does not rely on T/B lymphocytes or natural killer (NK) cells
but occurs in a myeloid-dependent manner (Cheng et al., 2014;
Quintin et al., 2012).
The C-type lectin receptor Dectin-1 is critical for Candida albi-
cans or b-glucan sensing, leading to immune training of mono-
cytes (Quintin et al., 2012). These primed macrophages show
heightenedproductionof proinflammatory cytokines to awide va-
riety of insults (Ifrim et al., 2013; Quintin et al., 2012). Dectin-1-
mediated training relies on activation of the PI3K (phosphoinosi-
tide 3-kinase)/mTOR (mammalian target of rapamycin) pathway
(Cheng et al., 2014). PI3K-induced Akt signaling is tightly regu-
lated by phosphoinositide phosphatases, which counterbalance
PI3K activity (Eramo and Mitchell, 2016). Among those phospha-
tases, the hematopoietic-restricted SHIP-1 (SH2-containing
inositol 50-phosphatase 1) (Kerr, 2011) is of particular interest, as
weshowed that it binds to the intracellular tail of Dectin-1 receptor
in granulocyte-macrophage colony-stimulating factor (GM-CSF)
bone marrow-derived cells (Blanco-Menéndez et al., 2015).
Because Candida albicans-induced trained immunity relies on
Dectin-1 and PI3K signaling, and SHIP-1 couples to Dectin-1
and counteracts PI3K function, we postulated that SHIP-1 tar-
geting could modulate trained immunity triggered by Dectin-1.
Our results indicate that SHIP-1 has a regulatory role in
b-glucan-induced training, affecting all hallmarks involved in
that process. Moreover, in vivo SHIP-1 deficiency in the myeloid
compartment improves protection conferred by trained immu-
nity. Notably, enhanced proinflammatory cytokine production
and better protection was also achieved by pharmacological
SHIP-1 inhibition in both mice and human peripheral blood
mononuclear cells (PBMCs), providing a potential therapeutic
approach to boost trained immunity.
RESULTS
SHIP-1 Deletion Boosts b-Glucan-Induced Trained
Immunity in Macrophages
Dectin-1 sensing of b-glucan induces trained immunity in
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Figure 1. SHIP-1 Deletion Boosts b-Glucan-Induced Trained Immunity in Macrophages
(A) SHIP-1 expression by WB, normalized to b-actin, in bone marrow-derived macrophages (BMDMs) exposed (+) or not () to b-glucan (whole glucan particles)
for the indicated time. Representative experiment of three performed.
(B) SHIP-1 protein expression in BMDMs. Representative experiment of six performed.
(C) Trained immunity in vitro model in mouse BMDMs. See also Figure S1A.
(D and E) Dectin-1 expression in BMDMs before b-glucan stimulation (D) or TLR4 expression both under non-trained (left) or b-glucan-primed (right) conditions,
just before LPS stimulation (E), according to Figure 1C. FACS histograms representative of four independent experiments. See also Figures S1B and S1C.
(F) BMDMswere stimulated (+) or not () with b-glucan or LPS, and IL-1b (left), IL-6 (middle), and TNFa production (right) was analyzed in supernatants according
to Figure 1C.
See also Figure S2. Independent experiments (N = 4 or 5) are shown. *p < 0.05 and **p < 0.01, paired Student’s t test comparingwild-type (WT) and LysMDSHIP-1.
#p < 0.05, paired Student’s t test comparing stimulated or not with b-glucan within the same genotype.marrow-derived macrophages (BMDMs) (Walachowski et al.,
2017). We initially stimulated BMDMs with purified particulate
b-glucan from S. cerevisiae, a well-known ligand for Dectin-1
(Rosas et al., 2008). SHIP-1 basal expression in BMDMs was
further induced after 1 day of b-glucan stimulation (Figure 1A).
To study the potential involvement of SHIP-1 in Dectin-1-
triggered trained immunity, we generated BMDMs from wild-
type (WT) mice or mice bearing a myeloid-specific deletion of
SHIP-1 in the myeloid compartment (LysMDSHIP-1) (Collazo
et al., 2012) (Figure 1B). Next, we adapted the proposed
in vitro long-term scheme of trained immunity (Quintin et al.,
2012) to IFN-g-primed BMDMs, evaluating whether trainingwith b-glucan boosts cytokine production in response to
lipopolysaccharide (LPS) (Figure 1C). Of note, as previously
described (Mosser and Zhang, 2008), IFN-g priming was
required to detect LPS-induced cytokines in BMDMs (Fig-
ure S1A), regardless of the induction of training. Surface expres-
sion of the receptors involved in b-glucan (Dectin-1; Figures 1D
and S1B) and LPS (TLR4; Figures 1E and S1C) recognition
were comparable between WT and LysMDSHIP-1 BMDMs. We
found that b-glucan-induced training resulted in increased cell
viability in WT BMDMs (Figure S2), concurring with previous re-
sults (Bekkering et al., 2016; Garcia-Valtanen et al., 2017). Non-
trained SHIP-1-deficient BMDMs showed higher viability thanCell Reports 25, 1118–1126, October 30, 2018 1119
their WT counterparts, but the relative cell number after b-glucan
training was similar between genotypes (Figure S2). To ensure
the analysis of cell-intrinsic responses as described (Bekkering
et al., 2016), cytokine production was normalized to the relative
cell number present in each treatment.
Pre-incubation of WT BMDMs with b-glucan prompted
a greater production of IL-1b and TNFa in response to LPS
(Figures 1F and S1A), reproducing trained immunity (Quintin
et al., 2012). Notably, b-glucan-trained LysMDSHIP-1 BMDMs
showed an increased production of these trained immunity-
associated cytokines compared with trained WT BMDMs (Fig-
ure 1F). Conversely, IL-6 was not induced following training or
in the absence of SHIP-1 in this setting (Figure 1F). Of note,
SHIP-1 deletion did not affect any of these inflammatory re-
sponses under non-trained conditions. These data indicate
that SHIP-1 modulates the extent of LPS-induced proinflamma-
tory cytokine production specifically during b-glucan training.
SHIP-1 Regulates Molecular andMetabolic Hallmarks of
Trained Immunity
We testedwhether theboost inb-glucan training in theabsenceof
SHIP-1wasaccompanied by regulation of key hallmarks involved
in the process. Regarding the molecular pathway, Akt was phos-
phorylated in response tob-glucan ina time-dependentmanner in
WTBMDMs (Figure 2A, left, and Figure S3A), concurringwith pre-
vious results (Chenget al., 2014).Notably, LysMDSHIP-1BMDMs
showed significantly increased and sustained Akt phosphoryla-
tion upon b-glucan stimulation (Figure 2A, left, and Figure S3A).
The analysis of mTOR targets, S6 and 4EBP1, also revealed a
maintained and significantly increased phosphorylation during
the treatment with b-glucan in SHIP-1-deficient BMDMs (Fig-
ure 2A, right, and Figure S3B). Of note, a basal activation of the
Akt pathway occurs in LysMDSHIP-1 BMDMs. This is consistent
with previous results in which the absence of SHIP-1 was associ-
ated with Akt overactivation and survival advantage (Antignano
et al., 2010; Wang et al., 2002), which would concur with our re-
sults in non-trained BMDMs (Figure S2).
Next, we measured the extracellular acidification rate (ECAR)
in b-glucan-trained BMDMs in a glycolysis stress test prior to
LPS stimulation (Figure 2B). Training with b-glucan for 5 days
increased ECAR inWTBMDMs, ametabolic shift that was signif-
icantly boosted in trained SHIP-1-deficient BMDMs (Figure 2B),
as reflected by enhanced basal (Figure 2C) and maximal (Fig-
ure 2D) glycolysis, together with a higher glycolytic reserve (Fig-
ure 2E). Increase in glycolytic reserve is the first metabolic signa-
ture associated with SHIP-1-deficient BMDMs upon b-glucan
training (Figure S4). Consistent with data on signaling pathway
activation (Figures 2A and S3), basal enhanced glycolysis was
found in LysMDSHIP-1 BMDMs (Figures 2C–2E and S4),
although it did not result in higher cytokine production unless
b-glucan-induced training was established (Figure 1F). These
results suggest that SHIP-1 controls the extent of the glycolytic
switch. Therefore, SHIP-1 deficiency may promote a pro-
glycolytic state that could boost inflammatory response upon
b-glucan-trained conditions.
To assess whether SHIP-1 could affect epigenetic reprogram-
ming induced by b-glucan, we tested the presence of the acti-
vating histone 3 Lys 4 trimethylation (H3K4me3) (Cheng et al.,1120 Cell Reports 25, 1118–1126, October 30, 20182014; Quintin et al., 2012). Chromatin immunoprecipitation
(ChIP) analysis showed that H3K4me3 was specifically enriched
by b-glucan training at TNFa promoter in WT BMDMs and
further augmented in trained SHIP-1-deficient macrophages
(Figure 2F), concurring with final enhanced TNFa production
(Figure 1F). Moreover, inhibition of histone methyltransferases
using 50-deoxy-50-(methylthio)adenosine (MTA) (Quintin et al.,
2012) abolished TNFa overproduction in the absence of
SHIP-1 upon training, whereas the histone demethylase inhibitor
pargyline (Quintin et al., 2012) did not have any effect (Figure 2G).
Considering that b-glucan-induced training relies also on histone
acetylation, training in the presence of the histone deacetylase
activator resveratrol (Cheng et al., 2014) or the histone acetyl-
transferase inhibitor EGCG (Ifrim et al., 2014) inhibited the
enhanced TNFa produced by trained SHIP-1-deficient macro-
phages (Figure 2H). These results highlight SHIP-1 as a regulator
of trained immunity by dampening the Akt/mTOR molecular
pathway and the glycolytic switch and relying on the epigenetic
reprogramming induced by b-glucan.
Myeloid-Specific Deletion of SHIP-1 Improves Trained
Immunity In Vivo
The generation of trained immunity in vivo leads to cross-protec-
tion against diverse secondary infections (Netea et al., 2016).
Signaling through PI3K is the canonical molecular pathway impli-
cated in the development of these trained responses (Arts et al.,
2016a; Cheng et al., 2014). To test the role of myeloid SHIP-1
in cytokine production under b-glucan training in vivo, WT and
LysMDSHIP-1 mice were challenged with LPS after training
with b-glucan (Cheng et al., 2014), and serum cytokines were
measured (Figure 3A). LPS-induced levels of IL-6 and TNFa
were increased in sera from WT mice upon b-glucan pre-treat-
ment (Figure 3B), indicative of the generation of a trained
response (Quintin et al., 2012). Notably, serum levels of IL-1b,
IL-6, and TNFa were further increased in LysMDSHIP-1 trained
mice compared with trained WT mice (Figure 3B), supporting
the regulatory role of SHIP-1 upon b-glucan training also in vivo.
Protective response against lethal systemic Candida albicans
infection by trained immunity relies on monocytes and macro-
phages (Quintin et al., 2012). After training with b-glucan, WT
and LysMDSHIP-1mice were intravenously infected with a lethal
dose of the clinical isolate C. albicans SC5314 (Figure 3C). Both
WT and LysMDSHIP-1 non-trained mice rapidly succumbed
upon these infectious conditions (Figure 3D, dashed lines), indi-
cating that SHIP-1 expression in the myeloid compartment is
redundant for the primary response to lethal candidiasis. The
protective effect of b-glucan administration against a lethal
C. albicans infection was significantly improved in LysMDSHIP-1
mice compared with WT littermates (Figure 3D, solid lines).
As trained immunity can be defined as a protection mecha-
nism from secondary lethal C. albicans infection induced by
a nonlethal encounter with the same pathogen (Quintin
et al., 2012), we trained mice with a low dose of C. albicans
followed by a lethal dose of the fungus (Figure 3E). Again, the
training stimulus enlarged the survival time of WT mice
and LysMDSHIP-1 trained mice were more resistant than WT
to lethal systemic candidiasis (Figure 3F, solid lines). Notably,
we observed enhanced production of IL-1b and TNFa inCandida
A
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Figure 2. SHIP-1 Regulates Molecular and Metabolic Hallmarks of Trained Immunity
(A) BMDMs were exposed to b-glucan for the indicated time, and phospho-Akt, Akt, phospho-S6, phospho-4EBP1, and b-actin were analyzed by WB.
Representative experiment of five performed. See also Figure S3.
(B–E) BMDMs were left untreated (dashed lines) or treated for 1 day with b-glucan (solid lines), washed, rested for 3 days, and re-plated in equal numbers for
determination of extracellular acidification rate (ECAR) in a glycolysis stress test upon sequential addition of glucose, oligomycin, and 2-deoxyglucose (2DG) as
indicated (B). Analysis of basal glycolysis (C), maximal glycolysis (D), and glycolytic reserve (E). See also Figure S4. Mean ± SEM (B) or individual data (C–E) of five
independent cultures are shown.
(F) BMDMs were trained (+) or not () with b-glucan for 1 day, washed, and rested for 4 days and chromatin immunoprecipitation (ChIP) against H3K4me3 was
performed in which enrichment on the TNFa promoter was analyzed using qPCR. Mean ± SEM of five independent experiments is shown.
(G and H) BMDMs were incubated (+) or not () with the methyltransferase inhibitor 50-deoxy-50-(methylthio)adenosine (MTA), the histone demethylase inhibitor
pargyline (G), the histone deacetylase activator resveratrol, or the histone acetyltransferase inhibitor EGCG (H) for 30 min before b-glucan training and after
wash-out. TNFa production was analyzed in supernatants after LPS stimulation according to Figure 1C. Individual data corresponding to three (G) or four (H)
independent experiments are shown.
In (C)–(H), *p < 0.05 and **p < 0.01, paired Student’s t test comparingWT and LysMDSHIP-1. In (C)–(F), #p < 0.05, paired Student’s t test comparing stimulated or
not with b-glucan within the same genotype.lethally infected kidneys from LysMDSHIP-1 trained mice (Fig-
ure 3G), together with a decreased renal fungal burden (Fig-
ure 3H). These data indicate that SHIP-1 deficiency in myeloidcells enhances b-glucan- and Candida-induced trained immu-
nity in vivo, improving the response to pathogen-specific or het-
erologous challenges.Cell Reports 25, 1118–1126, October 30, 2018 1121
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Figure 3. Myeloid-Specific Deletion of
SHIP-1 Improves Trained Immunity In Vivo
(A) In vivomodel of training by two intraperitoneal
(i.p.) b-glucan injections and secondary i.p. LPS
challenge for measuring serum cytokines.
(B) Mice were treated according to Figure 3A.
Serum was collected after 60 min (TNFa) or
90 min (IL-1b and IL-6) of LPS challenge, and
cytokines were analyzed.
(C) In vivo model of training as in (A) but with
secondary Candida albicans lethal infection.
(D) Survival curve according to Figure 3C.
(E) In vivo model of training by a systemic infec-
tion with a low dose of C. albicans followed
by a secondary lethal challenge with the same
pathogen.
(F) Survival curve according to Figure 3E.
(G and H) Renal cytokines on day 2 post-infection
(p.i.) (G) and kidney fungal burden (H) at indicated
time points p.i. were evaluated in trained mice,
following model in Figure 3E.
In (B), (G), and (H), single dots correspond to
individual mice. Mean ± SEM of two (B and H) or
three (G) pooled experiments is shown, including
at least 5 mice per condition. *p < 0.05 and
**p < 0.01, unpaired Student’s t test comparing
WT and LysMDSHIP-1. #p < 0.05, unpaired Stu-
dent’s t test comparing the same genotype
stimulated or not with b-glucan. In (D) and (F), a
pool of two experiments is shown, including
between 6 and 16 mice per group as indicated.
**p < 0.01, log rank test between WT and
LysMDSHIP-1 mice. #p < 0.05, log rank test
comparing trained or not with b-glucan (D) or
C. albicans (F) within the same genotype.Pharmacological Inhibition of SHIP-1 Enhances Trained
Immunity
The relevance of the PI3K pathway in distinct pathologies has
promoted the development of chemical SHIP-1 phosphatase in-
hibitors such as 3a-aminocholestane (3AC; SHIPi) (Brooks et al.,
2010). We thus tested 3AC as a potential tool to boost trained
immunity. BMDMs were trained with b-glucan in presence of
different doses of 3AC (half maximal inhibitory concentration
[IC50] = 13.5 mM; Brooks et al., 2015), and LPS-induced TNFa
was measured (Figure 4A). Upon b-glucan training, SHIP-1 inhi-
bition boosted TNFa production in a dose-dependent manner
(Figure 4B).
To analyze the effect of 3AC SHIPi under in vivo infectious
conditions, mice were administered SHIPi twice on consecu-
tive days following the published regimen (Gumbleton
et al., 2017), and coincident with the second day of 3AC
administration, mice were trained with a low dose of
C. albicans. Seven days later, mice were lethally infected
with the same fungus (Figure 4C). Inhibition of SHIP-1 did
not affect the survival of non-trained mice (Figure 4D, dashed1122 Cell Reports 25, 1118–1126, October 30, 2018lines) but improved the survival of
Candida-trained mice (Figure 4D, solid
lines).
To further explore the potential rele-
vance of the use of 3AC SHIPi, wetrained human PBMCs in the presence of SHIPi, rested and
stimulated with LPS, and cytokine production was measured
(Figure 4E). This scheme mirrors the stimulation pattern
proposed for human PBMCs elsewhere (Quintin et al., 2012).
Importantly, SHIP-1 inhibition boosted IL-1b, IL-6, and TNFa
production in these b-glucan-trained human PBMCs (Figure 4F).
Thus, our data indicate that SHIP-1 can be targeted with phar-
macological inhibitors in both mice and human cells to boost
trained immunity.
DISCUSSION
Herein, we define SHIP-1 in myeloid cells as a target to improve
trained immunity. Additionally, we provide a pharmacological
approach, the SHIP-1 inhibitor 3AC, improving training-induced
resistance to Candida infection and trained immunity in human
PBMCs. Because modulation of myeloid progenitors in the
bone marrow is an integral component of trained immunity (Mi-
troulis et al., 2018), and 3AC administration expands the hemato-
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Figure 4. Pharmacological Inhibition of
SHIP-1 Enhances Trained Immunity
(A) In vitro experimental model applied to mouse
BMDMs, indicating when the SHIP-1 inhibitor
(SHIPi) 3a-aminocholestane (3AC) was added.
(B) Mouse BMDMs were incubated with the SHIPi
at the indicated concentrations. TNFa production
was analyzed in supernatants of b-glucan-trained
cells after LPS stimulation according to Figure 4A.
Mean + SEM of four independent experiments is
shown. **p < 0.01, paired Student’s t test between
SHIPi-treated and non-treated cells.
(C) In vivomodel of training by a systemic infection
with a low dose of Candida albicans in the pres-
ence of SHIPi followed by a second lethal chal-
lenge with the same pathogen. When indicated,
the inhibitor was administered intraperitoneally.
(D) Survival curve of 0.3% hydroxypropylcellulose
(control) or SHIPi-treated mice according to Fig-
ure 4C. A pool of two experiments is shown,
including between 10 and 19 mice per group as
indicated. **p < 0.01, log rank test between trained
control and SHIPi-treated. #p < 0.05, log rank test
comparing trained or not with C. albicans within
the same treatment.
(E) In vitro experimental model applied to human
peripheral blood mononuclear cells (PBMCs)
indicating when SHIPi was added.
(F) IL-1b, IL-6, and TNFa production was analyzed
in supernatants of b-glucan-trained human
PBMCs after LPS stimulation according to Fig-
ure 4E. Samples from seven independent donors
are shown. *p < 0.05, paired Student’s t test.inhibition could also influence this compartment. Although
Candida-induced training and the primary response to the fun-
gus are T/B cell independent (Bär et al., 2014; Quintin et al.,
2012), systemic inhibition of SHIP-1 can also influence NK and
T cells (Gumbleton et al., 2017), and we cannot rule out indirect
effects on non-myeloid cells.
We show that SHIP-1 inhibition potentiates the canonical
PI3K/Akt activation pathway, which alsomediates trained immu-
nity in response to other stimuli such as the bacillus Calmette-
Guérin (BCG) vaccine (Arts et al., 2016a). SHIP-1 inhibition could
represent a broad strategy to boost trained immunity. Indeed,
SHIP-1 displays an inhibitory function in NOD2 signaling (Condé
et al., 2012), the BCG-mediated trained immunity pathway
(Kleinnijenhuis et al., 2012). Considering that BCG vaccination
confers cross-protection to human viral infections (Arts et al.,
2018b), SHIP-1 inhibitor could improve the protective effect of
BCG.
Enhanced trained immunity could raise as an important host
defense mechanism against infections or sepsis (Netea et al.,
2016). However, because diverse endogenous danger signals
from injured tissues can trigger innate immune memory hall-
marks (Crișan et al., 2016b), caution is needed regarding the
potential deleterious function of boosting trained immunity in
diseases characterized by excessive inflammation. This notion
could apply to atherosclerosis (Leentjens et al., 2018), cardio-vascular events (Hoogeveen et al., 2017), gout (Crișan et al.,
2016a), and a variety of autoimmune diseases and autoinflam-
matory disorders such as rheumatoid arthritis, systemic lupus
erythematosus, and hyper-IgD syndrome (Arts et al., 2018a), in
which monocytes and macrophages share a detrimental trained
immunity-like phenotype. Similarly, boosting microglia-depen-
dent training (Wendeln et al., 2018) through SHIP-1 inhibition
could be detrimental for neurological disorders and stroke.
Under these settings, SHIP-1 activators such as AQX-1125
(Stenton et al., 2013) could be potentially used to ameliorate
an excessive and detrimental activation of trained immunity.
In conclusion, although studies on trained immunity have
focused on the characterization of this phenomenon, strategies
to enhance trained immunity deserve further investigation. Our
data indicate that the trained immunity process can be boosted
by targeting SHIP-1 inmyeloid cells. Moreover, SHIP-1 inhibitors
could be proposed as potential pharmacological tools to
improve trained immunity in clinical settings in which enhance-
ment of inflammatory responses is beneficial.EXPERIMENTAL PROCEDURES
Mice and Human Samples
Mice were bred at Centro Nacional de Investigaciones Cardiovasculares
(CNIC) under specific pathogen-free conditions. WT C57BL/6J mice wereCell Reports 25, 1118–1126, October 30, 2018 1123
used for SHIP-1 inhibition experiments. LysM+/+SHIP-1flox/flox (WT) and
LysMCre/+SHIP-1flox/flox (LysMDSHIP-1) (Collazo et al., 2012) were kept as lit-
termates. Experiments were conducted with 8- to 12-week-old age-matched
mice (regardless of gender). Experiments were approved by the animal ethics
committee at CNIC and conformed to Spanish law under Real Decreto 1201/
2005. Animal procedures were also performed in accordance to European
Union (EU) Directive 2010/63EU and Recommendation 2007/526/EC.
Buffy coats from healthy volunteers were obtained from the Andalusian
Biobank after ethical approval was obtained from the local Instituto de Salud
Carlos III (ISCIII) Research Ethics Committee (PI 36_2017).
Trained Immunity In Vitro Models
BMDMs
BMDMs (105) were plated in 96-well plates (200 mL final volume; Corning) and
stimulated with R10 or 100 mg/mL b-glucan (whole glucan particles, Biothera)
for 24 hr. Then, cells were washed and rested 3 days in culture medium. On
day 4, unless indicated, BMDMs were washed again and primed with
25 ng/mL IFN-g (BD Biosciences) for 24 hr. On day 5, a final wash was per-
formed, and cells were stimulated with R10 or 1 mg/mL standard Escherichia
coli LPS (EK; Invivogen). To measure IL-1b production, following 4 hr of LPS
challenge, cells were further stimulated for 2 hr with 5mMATP (Sigma-Aldrich),
needed for inflammasome activation and pro-IL-1b processing (Schroder and
Tschopp, 2010), and supernatants were harvested for ELISA assay. For TNFa
and IL-6, after 24 hr of LPS stimulation, supernatants were collected for ELISA.
When required, BMDMs were pre-incubated for 30 min prior to b-glucan
stimulationwith 500 mM50-deoxy-50-(methylthio)adenosine (MTA), 6mMpargy-
line, 50 mM resveratrol, and 50 mM (-)-epigallocatechin-3-gallate (EGCG) (all
from Sigma-Aldrich). SHIP-1 inhibitor (SHIPi; 3AC; Calbiochem) was also
used at the indicated doses on b-glucan-trained BMDMs (toxic for non-trained
cells). Inhibitorswere also added in the firstwash-out, before the resting period.
To assess receptor expression and cell viability, 6 3 105 BMDMs were
plated in non-treated 24-well plates (1,200 mL final volume; Corning) and fol-
lowed the training scheme described above. Dectin-1 expression was evalu-
ated on day 0 prior to b-glucan addition. Cell viability and TLR4 expression
were assessed on day 5 before LPS stimulation. At indicated times, cells
were collected in PBS/EDTA and stained on ice-cold fluorescence-activated
cell sorting (FACS) buffer (PBS/EDTA plus 3% fetal bovine serum [FBS]) for
flow cytometry analysis.
For western blotting (WB) assays and ChIP analysis, 3 3 106 BMDMs were
plated in six-well plates (3 mL final volume; Corning) and stimulated with R10
or 200 mg/mL b-glucan (to maintain mass/cell ratio) for given times. ChIP was
performed on day 5, without IFN-g priming, as detailed below.
To address metabolic status, 3 3 106 BMDMs were plated in non-treated
6-well plates (3 mL final volume; Corning) and followed the training scheme
described above but with 200 mg/mL b-glucan (to maintain mass/cell ratio).
On day 4, without IFN-g priming, cells were detached in PBS/EDTA, plated
at 105 cells/well, and rested overnight in R10 prior to the Seahorse XF glycol-
ysis stress test (Agilent Technologies). When glycolytic metabolism was eval-
uated after overnight stimulation with b-glucan, BMDMs (105) were directly
plated in 96-well Seahorse cell culture plates (200 mL final volume; Agilent
Technologies) and stimulated with R10 or 100 mg/mL b-glucan the following
day.
PBMCs
Total PBMCs (5 3 105) were plated in 96-well plates (200 mL final volume) and
stimulated with 100 mg/mL b-glucan for 24 hr. Then cells were washed and res-
ted for6days inculturemedium.Onday7,PBMCswerestimulatedwith1mg/mL
LPS (EK). After24hr, supernatantswerecollected for IL-1b, IL-6, andTNFamea-
surement by ELISA. When required, b-glucan-trained PBMCs were pre-incu-
bated for 30 min with 10 mM 3AC (toxic for non-trained cells). Inhibitor was
also added together with the first wash-out, before the resting period.
To assess cell viability, 3 3 106 total PBMCs were plated in 24-well plates
(1,200 mL final volume; Corning) and followed the training scheme described
here. On day 7, prior to LPS stimulation, cells were collected in PBS/EDTA
and stained on ice-cold FACS buffer for flow cytometry analysis.
For normalization of cytokine production, the fold cell number in each con-
dition was calculated as follows: live cell number/live cell number in average
non-trained WT, according to Figure S2. In case of SHIP-1 inhibition experi-1124 Cell Reports 25, 1118–1126, October 30, 2018ments, non-treated cells were used as reference. Thus, cytokine production
was normalized per cell number as (absolute cytokine value/fold cell number)
in each condition.
In Vivo Models
Mice were trained with either two intraperitoneal (i.p.) injections of 1 mg
b-glucan particles on days 7 and 4 or 2 3 104 Candida albicans intrave-
nously (i.v.) on day 7. Sterile PBS was used as control. One week later,
mice were challenged with 5 mg E. coli LPS (serotype O55:B5; Sigma-Aldrich)
i.p., and blood was collected 60 min later to assess serum TNFa (Mouse TNFa
DuoSet; R&D Systems) or 90 min later to evaluate serum IL-1b and IL-6. Alter-
natively, mice were lethally infected with 23 106C. albicans i.v. andmonitored
daily for weight, general health, and survival, following institutional guidance.
For qPCR analysis of renal cytokines, RNA was purified from whole kidneys
on day 2 post-secondary infection (p.i.). Kidney fungal burden at indicated
time points p.i. was determined by plating organ homogenates obtained me-
chanically over 70 mm cell strainers (BD Biosciences) after slicing the tissue, in
serial dilutions on YPD agar plates; colony-forming units (CFUs) were counted
after growth at 30C for 48 hr, and data are shown as CFUs in total kidney.
When required, mice were i.p. treated with 0.11 mg 3AC on days 8 and
7. 3AC was diluted in PBS 0.3% hydroxypropylcellulose (Sigma-Aldrich),
used as control.
Quantification and Statistical Analysis
The statistical analysis was performed using Prism (GraphPad Software).
Unless specified, statistical significance for comparison between two sample
groups with a normal distribution (Shapiro-Wilk test for normality) was deter-
mined using two-tailed paired or unpaired Student’s t test. When groups
were too small to estimate normality, a Gaussian distribution was assumed.
Comparison of survival curves was carried out using the log rank (Mantel-
Cox) test. Outliers were identified by means of Tukey’s range test. Differences
were considered significant at p < 0.05 as indicated. Except when specified,
only significant differences are shown. As indicated in figure legends, either
a representative experiment or a pool is shown, and the number of repetitions
of each experiment and number of experimental units (either cultures or mice)
is indicated. In vitro experiments are shown as a pool of experiments, in
which linked WT-LysMDSHIP-1 dots represent independent cultures that
were processed within the same experiment. In this way, an internal compar-
ison between genotypes can be visually done. Different conditions within the
same genotype in a particular experiment, although not connected by amatter
of clarity, were also pair-analyzed, and statistically significant differences are
indicated by pound signs (#).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.09.092.
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Kleinnijenhuis, J., Lachmandas, E., Gonçalves, L.G., Belinha, A., et al. (2016a).
Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 17,
2562–2571.
Arts, R.J., Joosten, L.A., and Netea, M.G. (2016b). Immunometabolic circuits
in trained immunity. Semin. Immunol. 28, 425–430.
Arts, R.J.W., Joosten, L.A.B., and Netea, M.G. (2018a). The potential role of
trained immunity in autoimmune and autoinflammatory disorders. Front. Im-
munol. 9, 298.
Arts, R.J.W., Moorlag, S., Novakovic, B., Li, Y., Wang, S.Y., Oosting, M.,
Kumar, V., Xavier, R.J., Wijmenga, C., Joosten, L.A.B., et al. (2018b). BCG
vaccination protects against experimental viral infection in humans through
the induction of cytokines associated with trained immunity. Cell Host Microbe
23, 89–100.e5.
Bär, E., Whitney, P.G.,Moor, K., Reis e Sousa, C., and LeibundGut-Landmann,
S. (2014). IL-17 regulates systemic fungal immunity by controlling the func-
tional competence of NK cells. Immunity 40, 117–127.
Bekkering, S., Blok, B.A., Joosten, L.A., Riksen, N.P., van Crevel, R., and
Netea, M.G. (2016). In vitro experimental model of trained innate immunity in
human primary monocytes. Clin. Vaccine Immunol. 23, 926–933.
Bistoni, F., Vecchiarelli, A., Cenci, E., Puccetti, P., Marconi, P., and Cassone,
A. (1986). Evidence for macrophage-mediated protection against lethal
Candida albicans infection. Infect. Immun. 51, 668–674.
Blanco-Menéndez, N., Del Fresno, C., Fernandes, S., Calvo, E., Conde-Gar-
rosa, R., Kerr, W.G., and Sancho, D. (2015). SHIP-1 couples to the Dectin-1
hemITAM and selectively modulates reactive oxygen species production in
dendritic cells in response to Candida albicans. J. Immunol. 195, 4466–4478.
Brooks, R., Fuhler, G.M., Iyer, S., Smith, M.J., Park, M.Y., Paraiso, K.H.,
Engelman, R.W., and Kerr, W.G. (2010). SHIP1 inhibition increases immuno-
regulatory capacity and triggers apoptosis of hematopoietic cancer cells.
J. Immunol. 184, 3582–3589.Brooks, R., Iyer, S., Akada, H., Neelam, S., Russo, C.M., Chisholm, J.D., and
Kerr, W.G. (2015). Coordinate expansion of murine hematopoietic and mesen-
chymal stem cell compartments by SHIPi. Stem Cells 33, 848–858.
Cheng, S.C., Quintin, J., Cramer, R.A., Shepardson, K.M., Saeed, S., Kumar,
V., Giamarellos-Bourboulis, E.J., Martens, J.H., Rao, N.A., Aghajanirefah, A.,
et al. (2014). mTOR- and HIF-1a-mediated aerobic glycolysis as metabolic ba-
sis for trained immunity. Science 345, 1250684.
Collazo,M.M., Paraiso, K.H.T., Park, M.-Y., Hazen, A.L., and Kerr,W.G. (2012).
Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by
SHIP. Eur. J. Immunol. 42, 1785–1795.
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